NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

CapsoVision, Inc. (CV) Stock Analysis

CapsoVision, Inc. (CV) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CV

$6.80

+$0.12 (+1.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CV with… →

CV Key Statistics

As of Oct 21, 2026
Trading
Open
$6.73
Previous Close
$6.68
Day's Range
6.67–6.80
52-Week Range
4.50–15.37
Volume
171.30K
Valuation
Market Cap
$361.83M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
26.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.45
Financials (FY)
Revenue (FY)
$13.55M+15.29%
Net Income (FY)
−$25.32M
Profit marginThe share of revenue left as profit after all costs and taxes.
−214.74%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.21M
1-Year Return
+41.37%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
157.13K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CV closed at $6.80, +41.37% over 1 year.

CapsoVision, Inc. (CV) has a market capitalization of $361.83M.

In fiscal 2025, CV reported revenue of $13.55M.

CV Stock Return by Calendar Year

CapsoVision, Inc. (CV) return since Jul 2025: what $10,000 became

1 year
$10,000 $14,137
+41.37%
Since Jul 2025
$10,000 $19,429
+94.29%

If you had invested $10,000 in CapsoVision, Inc. (CV) at the close on July 2, 2025, the earliest close on record here, it would have been worth $19,429 at the close on October 21, 2026: +94.29% in total, +66.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−36.39%
2025 (partial year)+205.43%

As of October 21, 2026.

CV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$13.55M−$25.32M−186.8%
2024$11.76M−$19.90M−169.3%
2023$9.75M−$11.31M−115.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$13.55M$7.17M−$25.52M−$25.32M−186.8%
2024$11.76M$6.38M−$19.92M−$19.90M−169.3%
2023$9.75M$5.49M−$11.35M−$11.31M−115.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CV Valuation vs Medical Devices Median

Median of 145 stocks
MetricCVMedical Devices medianvs median
P/S ratio26.052.5310.3x the median
Profit margin−214.74%−14.78%200.0 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CapsoVision, Inc. (CV) carries a market capitalisation of $361.83M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 99 employees.

The 52-week range on file runs from $4.50 to $15.37. CV last closed at $6.80 on October 21, 2026. That is +$0.12 (+1.80%) against the previous close. The latest close sits 51.11% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $13.55M. That is +15.29% against the prior fiscal year, when revenue was $11.76M. The same year closed with a net loss of $25.32M. The reported profit margin is −214.74%. That is 200 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −0.45.

Across the 3 fiscal years on file, revenue moves from $9.75M in 2023 to $13.55M in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 26.05 times revenue. On price-to-sales that is 10.3 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +41.37%. Annualized volatility over the trailing 1 year is 98.33%.

Growth & Income

No dividend is on file for CV.

So far in 2026 the total return is −36.39%.

Peer Comparison

CapsoVision, Inc. (CV) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CapsoVision, Inc. CV $361.83M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. CapsoVision, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About CapsoVision, Inc.

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Visit website →